/주식/ASMB
ASMB

ASMB

USD

Assembly Biosciences Inc. Common Stock

$10.700+0.170 (1.614%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$10.530

고가

$10.970

저가

$10.530

거래량

0.00M

기업 기본 정보

시가총액

81.7M

산업

생명공학

국가

United States

거래 통계

평균 거래량

0.03M

거래소

NMS

통화

USD

52주 범위

저가 $7.75현재가 $10.700고가 $19.93

AI 분석 리포트

마지막 업데이트: 2025년 4월 23일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

ASMB: Assembly Biosciences Inc. Common Stock - What's Happening and What to Watch

Stock Symbol: ASMB Generate Date: 2025-04-23 14:56:16

Let's break down what's been going on with Assembly Biosciences and what the recent information might suggest.

Recent News Buzz: Mostly Positive Signals

Looking at the latest headlines, the general feeling around Assembly Biosciences seems pretty upbeat lately.

  • First off, the company shared some new details about one of their potential drugs, ABI-5366, which is aimed at treating herpes. They presented data showing it looks promising in terms of how it can be dosed and how well people tolerate it. That's good news because it means the drug candidate is moving forward and showing positive signs in studies.
  • Then came a big one: Guggenheim, a well-known investment bank, started covering the stock and slapped a "Buy" rating on it with a price target way up at $31. When a major firm initiates coverage with a strong buy and a high target, it often grabs attention and can signal confidence in the company's future prospects, especially its drug pipeline.
  • There was also a note from HC Wainwright, but they just kept their rating at "Neutral." This isn't negative, but it's not as strong a vote of confidence as the Guggenheim call.
  • Finally, the company reported its year-end financial results and highlighted that they have four drug candidates currently in clinical trials, with more data expected this year. This shows they're actively pushing their pipeline forward, which is key for a biotech company.

So, the main takeaway from the news is positive momentum driven by progress in their drug development and a notable endorsement from a new analyst covering the stock.

Price Check: Bouncing Off the Bottom?

Now, let's look at what the stock price itself has been doing. If you check the historical data over the past few months, ASMB saw a pretty significant drop, falling from the $14-$15 range back in January down to lows around $8-$9 in early April.

However, more recently, the price seems to have found some footing. It's bounced up from those April lows and is currently trading around the $10.40-$10.50 mark. This recent move suggests the selling pressure might have eased, and buyers are starting to step in around these levels.

The AI prediction for the very near term (today and the next couple of days) is pretty flat or slightly mixed – basically predicting minimal movement right around the current price. This doesn't point to a big immediate jump or drop, suggesting a period of potential consolidation after the recent bounce.

Putting It Together: What Might This Mean?

Considering the positive news flow, particularly the strong analyst rating and pipeline updates, combined with the stock price appearing to bounce off its recent lows, the situation might be starting to look more favorable for those interested in the stock.

The market seems to be reacting positively to the company's progress after a period of decline. The Guggenheim "Buy" rating with a high target provides a potential long-term bullish view from a professional firm.

  • Potential Lean: Based on this mix, the current situation could be seen as potentially favoring those looking to buy or add shares, especially if they believe in the company's drug pipeline and the analyst's long-term view. It doesn't scream "sell" right now, especially after the recent price drop.
  • Potential Entry Consideration: The stock has recently bounced from the low $8s and is now around $10.45. The recommendation data points out that the current price is just above the 20-day moving average (around $10.04) and near a support level ($10.09). This area around $10.00 to $10.45 could be considered a potential entry zone if you're looking to get in, as it aligns with recent support and the moving average.
  • Potential Exit/Stop-Loss Consideration: Managing risk is always key. If the recent bounce fails and the stock starts heading back down, a potential stop-loss level to consider might be around $9.37, as suggested by the recommendation data. This is below the recent bounce area. On the upside, the recommendation data suggests a potential take-profit around $11.09, which could act as a short-term target or resistance level. Remember, the analyst target is much higher ($31), but that's likely a longer-term view.

Company Context: Biotech Risks and Rewards

It's important to remember that Assembly Biosciences is a biotechnology company. Their value is heavily tied to the success of their drug candidates in clinical trials. News about trial data, like the recent herpes drug update, is therefore incredibly important. They are focused on viral diseases and have a collaboration with Gilead Sciences, which is a positive sign.

Also, keep in mind this is a relatively small company with a market cap around $78 million and lower trading volume compared to bigger stocks. This means the price can sometimes move quite sharply on news or trading activity. While the P/E ratio is negative (common for biotechs not yet profitable), the recommendation data notes it's less negative than the industry average, which they see as a value point, though other fundamentals like growth, ROE, and debt show weaknesses.

Putting it all together, ASMB has positive news momentum and a recent price bounce from lows, supported by a strong analyst rating. However, like all biotechs, it carries significant risk tied to clinical trial outcomes and fundamental challenges.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves significant risk, and you could lose money. Always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

관련 뉴스

GlobeNewswire

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – – Additional poster presentation

더 보기
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
Analyst Upgrades

Guggenheim Initiates Coverage On Assembly Biosciences with Buy Rating, Announces Price Target of $31

Guggenheim analyst Vamil Divan initiates coverage on Assembly Biosciences with a Buy rating and announces Price Target of $31.

더 보기
Guggenheim Initiates Coverage On Assembly Biosciences with Buy Rating, Announces Price Target of $31
Analyst Upgrades

HC Wainwright & Co. Reiterates Neutral on Assembly Biosciencesto Neutral

HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences from Neutral to Neutral.

더 보기
HC Wainwright & Co. Reiterates Neutral on Assembly Biosciencesto Neutral
GlobeNewswire

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures,

더 보기
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

AI 예측Beta

AI 추천

약세

업데이트 시간: 2025년 4월 28일 오전 10:30

약세중립강세

56.7% 신뢰도

리스크 & 트레이딩

리스크 수준3/5
중위험
적합 대상
가치
트레이딩 가이드

진입점

$10.54

익절

$11.36

손절

$9.54

핵심 요소

PDI 33.3이(가) ADX 12.6과 함께 MDI 30.8 위에 있어 강세 추세를 시사합니다.
현재 가격이 지지선($10.62)에 매우 근접하여 강력한 매수 기회를 시사합니다.
MACD 0.0729이(가) 신호선 0.0927 아래에 있어 약세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기